A factor IX mutation, verified by direct genomic sequencing, causes haemophilia B by a novel mechanism.
A novel factor IX gene mutation (factor IX London 2) has been characterized. This causes severe crm+ haemophilia B as the patient's plasma shows normal factor IX antigen level and less than 1% clotting activity. Sequence analysis of the entire cloned coding and promoter regions revealed a single point mutation: a G----A transition at position 31,119. This region of the patient's DNA was amplified in vitro by the polymerase chain reaction and the nucleotide change was confirmed by direct sequencing of the amplified products. The mutation results in the substitution of the arginine at position 333 by glutamine. This arginine residue is absolutely conserved in the catalytic domain of normal human and bovine factor IX, X and prothrombin. The substitution by glutamine causes the loss of a positive charge from the surface of the factor IX London 2 protein. This mutation pinpoints a previously unknown, functionally critical feature of factor IX which may be involved in substrate or co-factor binding.
Tsang
T C
TC
Division of Medical and Molecular Genetics, UMDS, London, UK.
Bentley
D R
DR
Mibashan
R S
RS
Giannelli
F
F
D001483:Base Sequence; D001665:Binding Sites; D015342:DNA Probes; D005164:Factor IX / Q000235:genetics*; D005784:Gene Amplification; D002836:Hemophilia B / Q000235:genetics*; D006801:Humans; D009154:Mutation; D012697:Serine Endopeptidases / Q000235:genetics; D013329:Structure-Activity Relationship
D015342:DNA Probes; D005164:Factor IX; D012697:Serine Endopeptidases